CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of tissues including bone and muscle, today announced results of a preclinical study with ACE-031, the company’s lead product for the treatment of muscle dystrophy, amyotrophic lateral sclerosis and cancer-related muscle loss, demonstrated that ACE-031 increased muscle mass despite concurrent treatment with glucocorticoids. These data were presented at the 12th International Congress of the World Muscle Society in Sicily, Italy.
